HealthcareLtd Gestione

Gestione criteri di controllo 4/4

HealthcareLtd Il CEO è Zhang Gen Ni, nominato in Oct2012, ha un mandato di 12.08 anni. possiede direttamente 33.97% delle azioni della società, per un valore di CN¥ 1.31B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 12.1 anni e 10.3 anni.

Informazioni chiave

Zhang Gen Ni

Amministratore delegato

CN¥804.8k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	12.1yrs
Proprietà del CEO	34.0%
Durata media del management	12.1yrs
Durata media del Consiglio di amministrazione	10.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Market Participants Recognise Healthcare Co.,Ltd.'s (SHSE:603313) Earnings

Sep 26

HealthcareLtd's (SHSE:603313) Profits Appear To Have Quality Issues

Sep 06

AMMINISTRATORE DELEGATO

Zhang Gen Ni (49 yo)

12.1yrs

Mandato

CN¥804,800

Compensazione

Mr. Zhang Gen Ni is Chairman of the Board & President of Healthcare Co., Ltd. since October 29, 2012. He was Chairman of the Board, General Manager and Director of Development Center of Healthcare Co., Ltd...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Zhang Gen Ni	Chairman of the Board & President	12.1yrs	CN¥804.80k	33.97% CN¥ 1.3b
Xiao Hong Wu	VP & Director	12.1yrs	CN¥441.40k	0.0053% CN¥ 205.3k
Hong Jian Zhang	VP & Director	12.1yrs	CN¥710.30k	0.0053% CN¥ 205.3k
Hailong Zhang	Accounting Supervisor	no data	Nessun dato	Nessun dato

12.1yrs

Durata media

51yo

Età media

Gestione esperta: Il team dirigenziale di 603313 è esperto e expertise (durata media dell'incarico 12.1 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Zhang Gen Ni	Chairman of the Board & President	12.1yrs	CN¥804.80k	33.97% CN¥ 1.3b
Xiao Hong Wu	VP & Director	12.1yrs	CN¥441.40k	0.0053% CN¥ 205.3k
Hong Jian Zhang	VP & Director	12.1yrs	CN¥710.30k	0.0053% CN¥ 205.3k
Jian Long Ji	Director	8.5yrs	CN¥474.10k	0.0053% CN¥ 205.3k
Tao Lin	Employee Supervisor	12.1yrs	Nessun dato	Nessun dato
Hua Wei	Member of Supervisory Board	12.1yrs	Nessun dato	Nessun dato
Chang Ling Zhu	Independent Director	5.6yrs	CN¥80.00k	Nessun dato
Baiming Xu	Independent Director	5.6yrs	CN¥80.00k	Nessun dato
Zaifa Cai	Independent Director	5.6yrs	CN¥80.00k	Nessun dato
Jian Sun	Chairman of the Supervisory Board	7.9yrs	Nessun dato	Nessun dato

10.3yrs

Durata media

52yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 603313 è composto da personale esperto e esperto (durata media dell'incarico 10.3 anni).

HealthcareLtd Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Healthcare Co.,Ltd., Annual General Meeting, May 17, 2024

Healthcare Co.,Ltd., Annual General Meeting, May 17, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

New minor risk - Financial position

Healthcare Co.,Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 18%

Market Participants Recognise Healthcare Co.,Ltd.'s (SHSE:603313) Earnings

Price target decreased by 60% to CN¥5.30

HealthcareLtd's (SHSE:603313) Profits Appear To Have Quality Issues

Second quarter 2024 earnings released: EPS: CN¥0.065 (vs CN¥0.19 in 2Q 2023)

Now 22% overvalued

Healthcare Co.,Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Healthcare Co.,Ltd., Annual General Meeting, May 17, 2024

Healthcare Co.,Ltd., Annual General Meeting, May 17, 2024

Healthcare Co.,Ltd. to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Shareholder dilution

Healthcare Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

New major risk - Financial position

Third quarter 2023 earnings released: EPS: CN¥0.031 (vs CN¥0.03 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.11 in 2Q 2022)

Now 20% undervalued

Price target decreased by 10% to CN¥12.68

First quarter 2023 earnings released: EPS: CN¥0.03 (vs CN¥0.06 in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.03 (vs CN¥0.59 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.12 loss in 2Q 2021)

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to CN¥15.00

Less than half of directors are independent

Third quarter 2021 earnings released: CN¥0.59 loss per share (vs CN¥0.42 profit in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target decreased to CN¥29.93

Second quarter 2021 earnings released: CN¥0.12 loss per share (vs CN¥0.17 profit in 2Q 2020)

Investor sentiment deteriorated over the past week

Price target decreased to CN¥28.03

Price target increased to CN¥52.73

Full year 2020 earnings released: EPS CN¥1.11 (vs CN¥1.18 in FY 2019)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

New 90-day high: CN¥43.05

New 90-day high: CN¥39.17

Investor sentiment improved over the past week

Market bids up stock over the past week

New 90-day high: CN¥36.87

Price target raised to CN¥46.61

Analysts update estimates

Healthcare Co., Ltd. to Report Q3, 2020 Results on Oct 31, 2020

Third quarter earnings released

Price target raised to CN¥36.16

Earnings released

New 90-day high - CN¥29.33

New 90-day high - CN¥26.83

Healthcare Co., Ltd. to Report First Half, 2020 Results on Aug 29, 2020

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media